Panion's epilepsy drug candidate shows positive initial results in a long-term study by CombiGene

Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.

Professor Merab Kokaia from Lund University, who has lead the study, expresses his joy over the results. CombiGene_PM_20171206_long-term_study.pdf

He explains that the study analyses three different parameters related to the epileptic brain.

  • Magnetic Resonance scanning (MR) evaluates the magnitude of damage in the brain;

  • Electro-encephalography (Video-EEG) observes the epileptic attacks and measures the electric activity of the brain during a seizure;

  • Histological analysis of the brain tissue that evaluates changes in the epileptic brain tissue compared to normal tissue and measures the expression of CG01 in the tissue. 

This film presents the study: (English subtitles).

"We congratulate CombiGene with the excellent performance of this important in-vivo study, which confirms our trust in the scientific robustness of the future treatment" says Anja Holm, CEO of Panion.. 


For further information, please contact:
Anja E. H. Holm, CEO | + 45-22 94 66 00 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 


Period October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -854 (-643).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -4 200 (-692).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.


Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.


Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.


Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.



Press releases and reports via E-mail.